Additional US installations and new order from Codonics
Pharmacolog's partner, Codonics Inc. recently delivered six WasteLog™ units to new hospitals and placed an additional order for nine WasteLog™ units for immediate delivery.
Pharmacolog's exclusive distributor and strategic partner Codonics, Cleveland, Ohio continues to supply WasteLog™ units to leading hospitals in the United States. Codonics has also ordered an additional nine WasteLog™ units from Pharmacolog for immediate delivery. Order value is approximately 2 MSEK.
The risk of narcotic drugs ending up in the wrong hands, so-called Drug Diversion, is a serious problem in healthcare. Every healthcare facility is vulnerable to Drug Diversion and must have a robust program to prevent it from occurring. An important part of such a program is an efficient and reliable waste control process. Interest in analytical equipment for waste screening of narcotic preparations is growing steadily and as a result Pharmacolog and Codonics are experiencing increased demand for WasteLog™.
Mats Högberg, CEO Pharmacolog comments: "Codonics is doing a fantastic job of marketing our solutions and we are now starting to see the results of the market launch at the end of last year. The number of inquiries is growing rapidly as the demand for efficient systems for so-called waste screening increases. Both companies are grateful to be part of the solution that helps prevent opioid and other drug abuse among healthcare professionals.”
For more information contact:
Mats Högberg, CEO
Email: [email protected]
Phone: +46 70-546 50 21
This information is insider information that Pharmacolog AB is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above, on September 16, 2022 at 15:45.
About Pharmacolog AB
Pharmacolog provides solutions and products that enhance work efficiency and safety when preparing injectable medication. Our goal is to help prevent medication errors and ensure maximum medication efficacy when treating patients with powerful yet potentially harmful injectable drugs. Pharmacolog’s products help staff at pharmacies and hospital wards minimize the risk of errors in the compounding process. Furthermore, by verifying that drugs and narcotics used in surgery have not been tampered with, our solutions also make a vital contribution to preventing drug diversion.
Further information regarding the company is available at www.pharmacolog.com.
The company's Certified Adviser is Mangold Fondkommission AB, which can be reached on telephone number +46 8-5030 15 50 or through [email protected].
BioStock Investor Meeting: Interview with OssDsign
In connection with the BioStock Investor Meeting in Stockholm, BioStock’s reporter was visited by Anders Svensson, CFO of OssDsign. Svensson told us more about OssDsign’s products for regenerative implants and patient-specific solutions for the treatment of bone defects. He also answered...
BioStock Investor Meeting: Intervju med OssDsign
I samband med BioStock Investor Meeting i Stockholm fick BioStocks reporter besök av Anders Svensson, CFO på OssDsign. Svensson berättade mer om OssDsigns produkter för regenerativa implantat och patientspecifika lösningar för behandling av bendefekter. Han svarade des...
aXichem announces indicative positive data from trail, regarding phenylcapcaisin’s effect on sports performance in athletes, carried out at University of Pablo Olavide, Spain
aXichem AB (publ), a developer of natural analogue industrial compounds and a leading neutraceuticals ingredient provider, today announces first indicative positive results from a finalized trial including aXivite®. The trial’s aim was to determine the effect of phenylcapsaicin and to evaluate its e...
aXichem tillkännager indikativa positiva data, avseende phenylcapcaisins effekt på elitidrottares prestationer, från en studie genomförd vid University of Pablo Olavide, Spanien
aXichem AB (publ), som utvecklar naturanaloga industrikemikalier och är en ledande leverantör av ingredienser till neutraceuticals, tillkännager idag de första indikativa positiva resultaten från en avslutad studie avseende aXivite®. Syftet med studien var att fastställa effekten av phenylcapsaicin...